Guerbet

2019 Revenue - Seite 2

CT/Cath Lab² sales grew 5.2% to €439.5 million at constant exchange rates thanks to double-digit sales growth of Optiray over the period (€444.6 million at current exchange rates). This strong growth, combined with the stability of Xenetix sales, illustrates Guerbet’s market penetration in this segment.

• Interventional Imaging now represents just over 9% of the Group’s revenue. It showed revenue at constant exchange rates of €73.5 million, up 12.5% (€75.5 million at current exchange rates).

Expected 2019 landing

The group expects an EBITDA³ margin of around 13.5% (excluding the positive impact of IFRS16 and excluding the €7.6 million impact of the final agreement with Mallinckrodt and Yves L’Epine’s transactional allowance). The group also anticipates a significant increase in cash flow, resulting especially from its inventory reduction initiatives and leading to a decrease in net debt of approximately €30 million for the 2019 financial year (excluding the effect of IFRS16).

¹ At constant exchange rates: amounts and rates of growth are calculated by cancelling out the exchange rate effect, which is defined as the difference between the indicator’s value for period N, converted at the exchange rate for period N-1, and the indicator’s value for period N-1.

² As a reminder, the MRI and CT/Cath Lab divisions now include sales of injection systems and related consumables.

³ EBITDA: Current operating income + net amortization, depreciation, and provisions.

 

Upcoming events:

Publication of 2019 annual results
24 March 2020 after trading

About Guerbet

Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, software and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. A pioneer since more than 90 years in the field of contrast media, Guerbet is a substantial investor in research and innovation with more than 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €817 million in revenue in 2019. For more information about Guerbet, please visit www.guerbet.com.